Ultime notizie per Addentax Group (NASDAQ:ATXG) Azioni

Addentax Group

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Addentax Group Corp

Northland Capital Markets analyst Ted Jackson downgrades Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) from Outperform to Market Perform and lowers the price target from $9 to $5.

News

Downgrades

Price Target

Analyst Ratings

Northland Capital Markets Downgrades Xos to Market Perform, Lowers Price Target to $5

WestPark Capital analyst Paul Rodriguez reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Hold.

Reiteration

CRWD

WestPark Capital Reiterates Hold on CrowdStrike Holdings

Rosenblatt analyst Barton Crockett maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Buy and raises the price target from $7.7 to $10.3.

QUAD

Rosenblatt Maintains Buy on Quad/Graphics, Raises Price Target to $10.3

"Alarum's fourth quarter 2024 revenues are estimated at $7.5 million ±3% and Adjusted EBITDA for the fourth quarter 2024 is expected to range from $1.3 million to $1.7 million."

Guidance

ALAR

Alarum Technologies Expects Q4 Revenue Of $7.5M ±3% Vs $7.48M Est

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) with a Buy and lowers the price target from $8 to $5.

CARM

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $5

WIIM

ELAB

Elevai Labs shares are trading lower after the company announced a 1-for-200 reverse stock split.

SNOW

Snowflake shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.

UXIN

Uxin shares are trading higher after the company reported Q2 sales of $70.85 million, up from $48.80 million year-over-year.

Macy's shares are trading lower after the company delayed its Q3 earnings release and conference call, citing an issue related to delivery expenses in one of its accrual accounts, prompting an independent investigation.

BBWI

Bath & Body Works shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its 2024 guidance.

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $325 to $385.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Raises Price Target to $385

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Biotech

Health Care

General

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Initiation

SRPT

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Cognition Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker(1) analysis from the Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau217(2) . Several blood-based measures of Alzheimer's disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients. These data provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system. &nbsp;

CGTX

Cognition Therapeutics Announced 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer's Disease Biology

Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.05 by 300 percent. The company reported quarterly sales of $7.194 million which beat the analyst consensus estimate of $7.000 million by 2.77 percent. This is a 6.58 percent increase over sales of $6.750 million the same period last year.

Earnings

Earnings Beats

Alarum Technologies Q3 2024 Adj. EPS $0.20 Beats $0.05 Estimate, Sales $7.194M Beat $7.000M Estimate

BHVN

Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary Outcome At Week 48 Compared To The Placebo+Standard Of Care Group

Contracts

SRM Entertainment Announces Order From An Orlando Theme Park For Its Misting Fans; Initial Order Of $820K For US Theme Parks And $85K For International Parks

AVXL

Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript Titled 'Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial' In A Reference Alzheimer's Disease Journal

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher premarket on Monday after the company successfully completed its 56th Electron mission and finalized a&nbsp;$23.9 million&nbsp;award from the U.S. Department of Commerce.
The company deployed five satellites into Low Earth Orbit for French IoT constellation operator Kinéis.
Rocket Lab&#8217;s &#8220;Ice AIS Baby&#8221; mission successfully launched from New Zealand on November 25, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42156903/rocket-lab-successfully-launches-two-missions-in-less-than-24-hours" rel="noreferrer noopener">deploying five satellites into a 643 km orbit.</a>
The company set a record for its fastest turnaround, completing the launch just 21 hours and 55 minutes after another mission in Virginia.
This marks Rocket Lab&#8217;s 14th mission of 2024 and its 56th overall, bringing its total satellites launched to 203.
Rocket Lab founder and CEO Sir Peter Beck said, &#8220;Two successful launches less than 24 hours apart from pads in different hemispheres. That&#8217;s unprecedented capability in the small launch market and one we&#8217;re immensely proud to deliver at Rocket Lab.&#8221;
Kinéis CEO Alexandre Tisserant, added, &#8221;With 15 Kinéis satellites now in orbit, we&#8217;re one step closer to the full deployment of our dedicated IoT constellation for transmitting data in near-real time, anywhere on the globe.&#8221;
Apart from this, in a seperate release, Rocket Lab disclosed that it finalized&nbsp;a $23.9 million award from the U.S. Department of Commerce to expand its compound semiconductor<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42160043/rocket-lab-signs-23-9m-chips-incentives-award-to-boost-semiconductor-manufacturing" rel="noreferrer noopener"> manufacturing in Albuquerque, New Mexico</a>.
These semiconductors are critical for space-grade solar cells and optoelectronic products essential to national security and commercial applications.
This month, the company also announced a multi-launch agreement with a confidential customer and was awarded a&nbsp;defense contract <a target="_blank" href="https://www.benzinga.com/news/contracts/24/11/41941068/rocket-lab-stock-is-blasting-off-wednesday-whats-going-on" rel="noreferrer noopener">worth up to $8 million</a>.
Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;SPDR S&amp;P Kensho Final Frontiers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKT#NYSE">ROKT</a>).
Price Action: RKLB shares are up 7.7% at $25.05 premarket at the last check Monday.
Photo via Company
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin" target="_blank" rel="noreferrer noopener">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Equities

Mid Cap

Movers

RKLB

ROKT

Why Is Rocket Lab USA Stock Surging Today?

Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo&nbsp;CRISPR-based investigational&nbsp;therapy designed as a single-dose treatment to inactivate the&nbsp;TTR&nbsp;gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
"This RMAT designation underscores the transformative potential of nex-z, our investigational in vivo CRISPR-based gene editing therapy for those living with hereditary ATTR amyloidosis with polyneuropathy," said Intellia President and Chief Executive Officer John Leonard, M.D. "It was granted following the FDA's review of our compelling interim Phase 1 data that indicated our one-time treatment led to rapid, deep and durable TTR reduction, which is expected to halt and potentially reverse the disease. We look forward to working closely with the FDA to bring this potential paradigm-shifting therapy to patients as quickly as possible."
The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of promising therapeutic candidates, including genetic therapies, that are intended to treat, modify, reverse or cure a serious or life-threatening disease. RMAT designation includes benefits, such as early interactions with the FDA, including discussions on surrogate or intermediate endpoints that could potentially support accelerated approval and satisfy post-approval requirements, and potential priority review of a product's biologics license application (BLA).
This RMAT designation is the third special regulatory designation received by Intellia for nex-z. Nex-z was also granted Orphan Drug Designation by the U.S. FDA and European Union Orphan Drug Designation by the European Commission.
About nexiguran ziclumeran (nex-z, also known as NTLA-2001) Based on Nobel Prize-winning CRISPR/Cas9 technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the&nbsp;TTR&nbsp;gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization&nbsp;collaboration&nbsp;with Regeneron.

Government

Regulations

NTLA

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

FLEX, PNST and CAN among pre-market losers

NEXI, MTC and MOLN among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Thursday morning as we check out all of the latest news moving shares today!



Moving stocks this morning are earnings reports, disclosed stakes in companies and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>JX Luxventure (NASDAQ:<a href="https://investorplace.com/stock-quotes/jxjt-stock-quote/">JXJT</a>) stock is rocketing more than 345% alongside heavy trading.</li>



<li>China Natural Resources (NASDAQ:<a href="https://investorplace.com/stock-quotes/chnr-stock-quote/">CHNR</a>) shares are soaring over 277% with strong early morning trading.</li>



<li>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) stock is surging more than 67% after Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) <a href="https://finance.yahoo.com/news/nvidia-reports-stakes-arm-soundhound-222448317.html">reported a stake in the company</a>.</li>



<li>Meihua International Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/mhua-stock-quote/">MHUA</a>) shares are gaining over 51% with strong pre-market trading today.</li>



<li>Nouveau Monde Graphite (NYSE:<a href="https://investorplace.com/stock-quotes/nmg-stock-quote/">NMG</a>) stock is increasing more than 45% after <a href="https://www.businesswire.com/news/home/20240214552719/en/NMG-Announces-Offtake-Agreement-with-GM-for-Canadian-Graphite-and-US150-Million-Equity-Investment">signing a supply agreement</a> with General Motors (NYSE:<a href="https://investorplace.com/stock-quotes/gm-stock-quote/">GM</a>).</li>



<li>Nano X Imaging (NASDAQ:<a href="https://investorplace.com/stock-quotes/nnox-stock-quote/">NNOX</a>) shares are rising over 38% as Nvidia also revealed a stake in this company.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) stock is climbing more than 38% on Thursday morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are jumping over 26% with heavy pre-market trading.</li>



<li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock is getting a 25% boost this morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are up more than 24% as it sees strong trading early this morning.</li>
</ol><h2>Top 10 Losers</h2>



<ol><li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is plummeting close to 44% after releasing a <a href="https://www.nasdaq.com/press-release/treasure-global-reports-second-quarter-fiscal-year-2024-results-2024-02-14">mixed fiscal Q2 2024 earnings report</a>.</li>



<li>Cineverse (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnvs-stock-quote/">CNVS</a>) shares are retreating over 37% following the <a href="https://www.nasdaq.com/press-release/cineverse-reports-third-quarter-fiscal-year-2024-results-2024-02-14">release of its Q3 earnings report</a>.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) stock is tumbling more than 31% after <a href="https://www.nasdaq.com/press-release/renalytix-reports-financial-results-for-second-quarter-of-fiscal-year-2024-2024-02-15">releasing results for its latest quarter</a>.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are taking an over 30% beating on Thursday morning.</li>



<li>Clean Energy Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/cety-stock-quote/">CETY</a>) stock is sliding more than 28% without any obvious news today.</li>



<li>Earlyworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/elws-stock-quote/">ELWS</a>) stock is pulling back over 29% <a href="https://investorplace.com/2024/02/why-is-earlyworks-elws-stock-up-340-today/">after a massive rally yesterday</a>.</li>



<li>Upexi (NASDAQ:<a href="https://investorplace.com/stock-quotes/upxi-stock-quote/">UPXI</a>) shares are falling more than 26% <a href="https://finance.yahoo.com/news/upexi-reports-fiscal-second-quarter-210500871.html">following a rough Q2 earnings report</a>.</li>



<li>Addentax (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxg-stock-quote/">ATXG</a>) stock is dropping over 26% with its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318065266&amp;type=PDF&amp;symbol=ATXG&amp;cdn=1f758177ea2228606438e3a5fa8aaf7f&amp;companyName=Addentax+Group+Corp.&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-02-14">latest earnings release</a>.</li>



<li>Healthcare Triangle (NASDAQ:<a href="https://investorplace.com/stock-quotes/hcti-stock-quote/">HCTI</a>) shares are slipping more than 25% <a href="https://seekingalpha.com/news/4067041-healthcare-triangle-stock-jumps-on-new-saas-solution-to-drive-ai-integration-in-healthcare?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">following a rally late yesterday</a>.</li>



<li>United States Antimony&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/uamy-stock-quote/">UAMY</a>) stock closes out our pre-market stock movers down over 24%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-feb-15th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

ATXG, CETY and TELO among pre-market losers

These Industrials stocks are trading higher:-Intuitive Machines Inc (LUNR) stock is trading at $6.80, a rise of $1.82, or 37.15%, on high volume.  Intuitive Machines Inc gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.63.  -Guar

Industrials Stocks Making Moves Thursday: LUNR, GFAI, LICN, MPU, ATXG, MTW, UGRO, UPWK

Addentax signs MOU to develop AI logistics system

Addentax signs MOU to develop AI logistic system

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Addentax Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxg-stock-quote/">ATXG</a>) just reported results for the fourth quarter of 2023.<ul><li>Addentax Group reported earnings per share of 29 cents.</li><li>The company reported revenue of $1.30 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/07/atxg-stock-earnings-addentax-group-for-q4-of-2023/">ATXG Stock Earnings: Addentax Group Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATXG Stock Earnings: Addentax Group Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Addentax Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxg-stock-quote/">ATXG</a>) just reported results for the first quarter of 2024.<ul><li>Addentax Group reported earnings per share of -25 cents.</li><li>The company reported revenue of $851,033.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/atxg-stock-earnings-addentax-group-for-q1-of-2024/">ATXG Stock Earnings: Addentax Group Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATXG Stock Earnings: Addentax Group Reported Results for Q1 2024

Addentax Group Corp. has announced the signing of a Memorandum of Understanding, or MOU, for nationwide strategic cooperation with Shenzhen Yingbin...

ATX Group, Inc. signs MOU for strategic cooperation with Shenzhen Yingbin Brand

ABAT

ABVC

AISP

ATXG

AUPH

BBLG

BETS

BNZI

BREA

BTBT

BTDR

CETY

CHNR

CLSK

CNVS

DBGI

ELWS

ESPR

FLEX

FRES

FSLY

FWBI

GFAI

GREE

GRNQ

HALL

HCTI

HIVE

ICCT

IINN

JXJT

LEXX

LICN

LUNR

MANU

MARA

MBLY

MHUA

MOLN

NEXI

NNOX

OTLY

PNST

RIOT

RNLX

ROMA

SABR

SCPX

SCYX

SIDU

SOUN

TELO

TWLO

UAMY

UGRO

UPWK

UPXI

WULF

YETI

ZCAR

Press Releases

Addentax Group Corp. Announces Signing of MOU for Strategic Cooperation with Zhongjiu Yihe

Addentax Group Corp. is Launching "Tourism-As-A-Service" Platform with Artificial Intelligence and Block-Chain Tools to Incubate Local and Overseas Pan-Entertainment and Tourism Services

Addentax Group Corp. and Regina Miracle International (Holdings) Limited Entered into a Collaboration Agreement to Enhance Textile and Garment Industry Services

Addentax Group Corp. and Dezhong Xinghui Collaborate to Develop AI Logistic System, Facilitating Breakthroughs in Logistics Delivery

Addentax Group Corp. Announces Private Placements of its Common Stock

Addentax Group Corp. Announces Signing of MOU for Strategic Cooperation with Shenzhen Yingbin Brand Development Co., Ltd.

Air T

Air Transport Services Group, Inc - Common Stock

Air Transport Services Gr

BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

BEST

C.H. Robinson Worldwide, Inc. - Common Stock

C.H. Robinson Worldwide

Freightos

Expeditors International of Washington, Inc. Common Stock

Expeditors Intl

FedEx

BingEx Limited - American Depositary Shares

BingEx

Freight Technologies, Inc. - Ordinary Shares

Freight Technologies

Forward Air

Globavend Holdings

GXO Logistics

Hub Group

Jayud Global Logistics Limited - Class A Ordinary Shares

Jayud Global Logistics

PS International Group Ltd. - Ordinary Shares

PS International Group

Radiant Logistics

Shengfeng Development Limited - Class A Ordinary Shares

Shengfeng Development

United Parcel Service

ZTO Express (Cayman) Inc. American Depositary Shares, each representing one Class A ordinary share.

ZTO Express (Cayman)

Comments

Addentax Group

Notizie

Ultime notizie per Addentax Group (NASDAQ:ATXG) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO